Canada markets close in 1 hour 44 minutes

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2950+0.0450 (+1.38%)
As of 02:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close3.2500
Open3.1300
Bid3.2600 x 5800
Ask3.8800 x 2000
Day's Range2.9000 - 3.4200
52 Week Range0.7707 - 35.6000
Volume2,112,715
Avg. Volume10,209,954
Market Cap31.635M
Beta (5Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-9.6000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.58
  • GlobeNewswire

    Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Cla

  • GlobeNewswire

    Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

    Wa'el Hashad Wa'el Hashad, CEO, Longeveron – FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – – Second designation received for Lomecel-B™ for the treatment of mild Alzheimer’s Disease after Regenerative Medicine Advanced Therapeutics (RMAT) Designation announced on July 9, 2024 – – Phase 2a Lomecel-B™ data in mild Alzheimer’s Disease selected for Featured Research Session oral presentation and poster presentation at upcoming Alzheimer’s Ass

  • GlobeNewswire

    Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

    - Lomecel-B™ appears to be the first cellular therapeutic candidate to receive RMAT designation for Alzheimer’s Disease Wa'el Hashad Wa'el Hashad, CEO, Longeveron Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular ther